To elucidate whether the reduction of cell viability upon imetelstat treatment was mediated via the oncogene-driven JAK-STAT pathway, we evaluated alterations in JAK2V617F downstream signaling by Western blotting upon 24 h of imetelstat or MM control treatment. The gene discussed is SOAT1; the disease is Miyoshi myopathy.